{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:21:40Z","timestamp":1790162500976,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic lymphocytic leukemia (CLL) is characterized by chronic clonal expansion of mature CD19-expressing B lymphocytes and global dysfunction of immune effectors, including natural killer (NK) cells. CLL remains incurable, and novel approaches to refractory CLL are needed. Our group has previously described trispecific killer engager (TriKE) molecules that redirect NK cell function against tumor cells. TriKE reagents simultaneously bind an activating receptor on NK cells, CD16, and a tumor antigen while also providing an NK cell expansion signal via an interleukin-15 moiety. Here we developed the novel CD19-targeting 161519 TriKE. We demonstrate that 161519 TriKE induced killing of a CD19-expressing Burkitt\u2019s lymphoma cell line and examined the impact on primary CLL targets using healthy donor and patient NK cells. 161519 TriKE induced potent healthy donor NK cell activation, proliferation, and directed killing. Furthermore, 161519 TriKE rescued the inflammatory function of NK cells obtained from CLL patient peripheral blood samples. Finally, we show that 161519 TriKE induced better directed killing of CLL in vitro when compared with rituximab. In conclusion, 161519 TriKE drives a potent activating and proliferative signal on NK cells, resulting in enhanced NK cell expansion and CLL target killing. Our findings indicate the potential immunotherapeutic value of 161519 TriKE in CLL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018029371","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T16:46:17Z","timestamp":1553013977000},"page":"897-907","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":84,"title":["Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-0634","authenticated-orcid":false,"given":"Martin","family":"Felices","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behiye","family":"Kodal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hinderlie","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cooley","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4587-3238","authenticated-orcid":false,"given":"Daniel A.","family":"Vallera","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-4944","authenticated-orcid":false,"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"issue":"1","key":"2020021109192414900_B1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"2020021109192414900_B2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s10020-018-0001-1","article-title":"Critical molecular pathways in CLL therapy","volume":"24","author":"Ferrer","year":"2018","journal-title":"Mol Med"},{"issue":"2","key":"2020021109192414900_B3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2020021109192414900_B4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bmt.1705619","article-title":"Graft-versus-leukemia in chronic lymphocytic leukemia","volume":"39","author":"Ben-Bassat","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"2020021109192414900_B5","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"issue":"303","key":"2020021109192414900_B6","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"2020021109192414900_B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"25","key":"2020021109192414900_B8","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2020021109192414900_B9","doi-asserted-by":"crossref","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"OncoImmunology"},{"issue":"11","key":"2020021109192414900_B10","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00262-010-0896-z","article-title":"Allogeneic natural killer cells for refractory lymphoma","volume":"59","author":"Bachanova","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2020021109192414900_B11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/imr.12157","article-title":"The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT)","volume":"258","author":"Foley","year":"2014","journal-title":"Immunol Rev"},{"issue":"6","key":"2020021109192414900_B12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/PPO.0000000000000156","article-title":"Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer","volume":"21","author":"Davis","year":"2015","journal-title":"Cancer J"},{"issue":"1 suppl","key":"2020021109192414900_B13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2011.10.033","article-title":"NK cells--from bench to clinic","volume":"18","author":"Murphy","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020021109192414900_B14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20051143","article-title":"Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells","volume":"202","author":"Bryceson","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"2020021109192414900_B15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"key":"2020021109192414900_B16","doi-asserted-by":"crossref","first-page":"861920","DOI":"10.1155\/2011\/861920","article-title":"Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy","volume":"2011","author":"Meazza","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"2020021109192414900_B17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021109192414900_B18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/2326-6066.CIR-17-0279","article-title":"IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56bright NK cells and increases NK-cell cytokine release capabilities","volume":"5","author":"Dubois","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2020021109192414900_B19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"issue":"23","key":"2020021109192414900_B20","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"2020021109192414900_B21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2020021109192414900_B22","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4143\/crt.2016.491","article-title":"Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity","volume":"49","author":"Schmohl","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"7","key":"2020021109192414900_B23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/mt.2016.88","article-title":"Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker","volume":"24","author":"Schmohl","year":"2016","journal-title":"Mol Ther"},{"issue":"45","key":"2020021109192414900_B24","doi-asserted-by":"crossref","first-page":"73830","DOI":"10.18632\/oncotarget.12073","article-title":"Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker","volume":"7","author":"Schmohl","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"2020021109192414900_B25","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2020021109192414900_B26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/bloodadvances.2018018176","article-title":"Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells","volume":"2","author":"Don Yun","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2020021109192414900_B27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","article-title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS","volume":"2","author":"Sarhan","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2020021109192414900_B28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0161-5890(99)00057-7","article-title":"Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2\/neu\/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis","volume":"36","author":"McCall","year":"1999","journal-title":"Mol Immunol"},{"issue":"6","key":"2020021109192414900_B29","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.4049\/jimmunol.0901244","article-title":"Novel human interleukin-15 agonists","volume":"183","author":"Zhu","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"2020021109192414900_B30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0022-1759(96)00115-9","article-title":"Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry","volume":"196","author":"Kipriyanov","year":"1996","journal-title":"J Immunol Methods"},{"issue":"12","key":"2020021109192414900_B31","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2020021109192414900_B32","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","article-title":"Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2020021109192414900_B33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.smim.2017.07.011","article-title":"Natural killer cells unleashed: checkpoint receptor blockade and BiKE\/TriKE utilization in NK-mediated anti-tumor immunotherapy","volume":"31","author":"Davis","year":"2017","journal-title":"Semin Immunol"},{"key":"2020021109192414900_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.10.004","article-title":"IL-15 signaling in NK cell cancer immunotherapy","volume":"44","author":"Rautela","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"2020021109192414900_B35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1159\/000481946","article-title":"Cellular immunotherapy in B-cell malignancy","volume":"40","author":"Schwarzbich","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"1","key":"2020021109192414900_B36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/6\/897\/1554766\/advances029371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/6\/897\/1554766\/advances029371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:54:19Z","timestamp":1581414859000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/6\/897\/246727\/Novel-CD19targeted-TriKE-restores-NK-cell-function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018029371","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]}}}